Erythropoietin

Erythropoietin: Is it worth it? Carriella Starnes Emory & Henry College Over a century ago Eugene Goldwasser and Takaji Miyake worked together in Chicago to synthesize the human hormone erythropoietin, better known as EPO. It took over 10 years for EPO to be approved by the Food and Drug Administration to be used solely for patients with anemia. EPO is naturally produced by the kidneys and is sensitive to the oxygen levels in the blood. When oxygen levels are too low, EPO is released

Erythropoietin secretion is regulated in the kidneys; it is an acidic glycoprotein, produced primarily in the renal cortex (Jelkmann, 2011). Two events happen to stimulate the release of erythropoietin. First, a transcription factor called GATA-2 (which prohibits Erythropoietin secretion in the presence of normal oxygen levels) decreases in instances of hypoxia allowing for erythropoietin secretion. Second, certain transcription factors called

focusing on for this issues analysis will be- Erythropoietin- Blood doping and Anabolic steroid’s Paragraph 1: Some of the variants of drugs that are most commonly utilized in sports is Erythropoietin, blood doping, anabolic steroids and human growth hormones. Erythropoietin is a drug that can be used to increase an athlete’s performance. Some of the side effects of using Erythropoietin are major and can be fatal, the side effects of using Erythropoietin are increased viscosity of the blood meaning

In the article titled “Testing for Recombinant Erythropoietin,” by Delanghe JR, Bollen M, and Beullens M, the intended audience is able to recognize the data and discussions presented in this article, as a review of a research study that had been conducted. Review articles are distinguishable from other scientific articles due to the format in which the article is designed. This article in particular included several of these distinguishable factors, such as the overall discussions on specific tests

THE HAEMATOLOGICAL PATTERN OF THE PATIENTS WITH CHRONIC KIDNEY DISEASE IN A TERTIARY CARE SETUP IN SOUTH INDIA Dr.S.Palaniandavan** Dr.M.V.Bhargavi*** *Professor and head of the department **Assistant professor General medicine department Sree Balaji medical college and hospital, Chromepet, Chennai. ABSTRACT Background: With the incidence and the prevalence of chronic kidney disease (CKD) increasing worldwide and its economic repercussions, a detailed haematological workup of such

and is affiliated with erythropoietin receptor (Epor) in erythroid cells (1, 2). A mutation in Tfr2 leads to an iron overload disease known as haemochromatosis (Hfe) type 3, without any apparent erythroid irregularities (1). Tfr2 is a constituent of an atypical iron-sensing pathway that adapts erythrocyte production, according to iron accessibility, achievable by modulating the erythroblast erythropoietin sensitivity (1). The red blood cell (RBC) specific hormone erythropoietin (Epo) accounts for the

Erythropoietin (EPO), blood doping, human growth hormones, steroid, beta-2 agonists. These are a few substances that come into mind when discussing the topic 'performance enhancing drug ' also known as doping. Doping is defined as the use of drugs to enhance performance and gain advantage over the other competitors, and it has been an ongoing problem in the sport community since the early centuries, with an increasing trend showing today. Envision yourself competing against an opponent who has been

Artificial erythropoietin can also be used. By increasing the number of erythropoietin in your blood you increase the amount of oxygen that can be brought to your muscles and organs, resulting in fewer discomfort in muscles during workout and more endurance, stamina, and enhanced performance. Blood

Megha Patel Journal article PSCI 1722 Erythropoietin in preterm infants Citation: Fauchere J, Koller B, Tschopp A et al., Safety of Early High-Dose Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants, The Journal of Pediatrics (167)1, 52-57, 2015. Background: The article, which was published in July 2015 in journal of pediatrics, gives an idea about the safe use of erythropoietin in preterm infants for protection of nervous system. Premature birth has remained one of the major

2014). As CKD continues to become worse, the individual is at higher risk for developing anemia. More than 40% of patients in stage V CKD develop anemia (Shemin, 2014). CKD leads to anemia due to a decrease or deficit in the production of erythropoietin (EPO) (Shemin, 2014). Bone marrow receptors are stimulated by EPO, a 165 amino acid protein, the stimulation leads to the production and promotion of red blood cell precursors into mature erythrocytes (Shemin, 2014). Since EPO is synthesized